作者:Sophie Canova、Véronique Bellosta、Antony Bigot、Patrick Mailliet、Serge Mignani、Janine Cossy
DOI:10.1021/ol062642i
日期:2007.1.1
Hsp90 has recently emerged as a promising biological target for treatment of cancer. Herbimycin A and other members of the benzoquinoid ansamycin class of natural products are known to inhibit Hsp90 activity. The total synthesis of herbimycin A was achieved from the commercially available Roche ester 1 by using allylmetals to control the stereogenic centers at C6, C7, C10, C11, and C12 and a ring-closing metathesis to control the (Z)-double bond of the (E,Z)-dienic moiety.